Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
AstraZeneca
AZN
|
+$810M |
| 2 |
Intuitive Surgical
ISRG
|
+$705M |
| 3 |
S&P Global
SPGI
|
+$439M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$361M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$253M |
Top Sells
| 1 |
Broadcom
AVGO
|
+$605M |
| 2 |
FedEx
FDX
|
+$587M |
| 3 |
Monster Beverage
MNST
|
+$395M |
| 4 |
McDonald's
MCD
|
+$387M |
| 5 |
Booking.com
BKNG
|
+$380M |
Sector Composition
| 1 | Technology | 22.3% |
| 2 | Consumer Discretionary | 16.25% |
| 3 | Healthcare | 15.51% |
| 4 | Financials | 12.99% |
| 5 | Communication Services | 11.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHS
551
DELISTED
Chicos FAS, Inc.
CHS
| $1.15M | ﹤0.01% |
132,492
-27,448
| -17% | -$238K |
|
|
SAFM
552
DELISTED
Sanderson Farms Inc
SAFM
| $1.15M | ﹤0.01% |
11,105
-326
| -3% | -$33.7K |
|
553
Sociedad Química y Minera de Chile
SQM
$12B
| $1.09M | ﹤0.01% |
23,778
+232
| +1% | +$10.6K |
|
554
Mueller Water Products
MWA
$3.86B
| $1.03M | ﹤0.01% |
89,132
-71,126
| -44% | -$819K |
|
|
HF
555
DELISTED
HFF Inc.
HF
| $1.02M | ﹤0.01% |
23,936
-7,217
| -23% | -$307K |
|
|
XENT
556
DELISTED
Intersect ENT, Inc
XENT
| $1.01M | ﹤0.01% |
35,260
-1,277,160
| -97% | -$36.7M |
|
|
PMT
557
PennyMac Mortgage Investment
PMT
$1.08B
| $1.01M | ﹤0.01% |
+50,036
| New | +$1.01M |
|
558
PagSeguro Digital
PAGS
$2.7B
| $977K | ﹤0.01% |
35,324
+345
| +1% | +$9.54K |
|
559
Globus Medical
GMED
$7.89B
| $947K | ﹤0.01% |
16,682
-217
| -1% | -$12.3K |
|
560
Artisan Partners
APAM
$3.27B
| $946K | ﹤0.01% |
29,194
-368
| -1% | -$11.9K |
|
|
RVNC
561
DELISTED
Revance Therapeutics, Inc.
RVNC
| $864K | ﹤0.01% |
34,753
-1,097,207
| -97% | -$27.3M |
|
|
CLDT
562
Chatham Lodging
CLDT
$349M
| $849K | ﹤0.01% |
40,624
-514
| -1% | -$10.7K |
|
563
Accenture
ACN
$151B
| $845K | ﹤0.01% |
4,964
+3,570
| +256% | +$608K |
|
564
Intuit
INTU
$183B
| $840K | ﹤0.01% |
3,696
-1,126
| -23% | -$256K |
|
|
RNTX
565
Rein Therapeutics, Inc. Common Stock
RNTX
$27.7M
| $835K | ﹤0.01% |
15,185
+120
| +0.8% | +$6.6K |
|
566
Credicorp
BAP
$21B
| $829K | ﹤0.01% |
3,718
+36
| +1% | +$8.03K |
|
567
Medpace
MEDP
$13.4B
| $820K | ﹤0.01% |
13,682
-2,431
| -15% | -$146K |
|
568
Acadia Realty Trust
AKR
$2.54B
| $808K | ﹤0.01% |
28,836
-2,737
| -9% | -$76.7K |
|
569
Myriad Genetics
MYGN
$642M
| $803K | ﹤0.01% |
17,457
-11,147
| -39% | -$513K |
|
570
Baidu
BIDU
$37B
| $794K | ﹤0.01% |
3,470
-2,662
| -43% | -$609K |
|
|
AMED
571
DELISTED
Amedisys
AMED
| $785K | ﹤0.01% |
6,282
-73
| -1% | -$9.12K |
|
572
Hamilton Lane
HLNE
$6.55B
| $777K | ﹤0.01% |
17,537
-222
| -1% | -$9.84K |
|
|
MRO
573
DELISTED
Marathon Oil Corporation
MRO
| $775K | ﹤0.01% |
33,292
+2,948
| +10% | +$68.6K |
|
|
ONC
574
BeOne Medicines Ltd. American Depositary Shares
ONC
$34.5B
| $762K | ﹤0.01% |
4,427
+43
| +1% | +$7.4K |
|
575
Nektar Therapeutics
NKTR
$916M
| $758K | ﹤0.01% |
+829
| New | +$758K |
|